PROKLAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Proklar, and when can generic versions of Proklar launch?
Proklar is a drug marketed by Forest Pharms and is included in one NDA.
The generic ingredient in PROKLAR is sulfamethizole. There are four drug master file entries for this compound. Additional details are available on the sulfamethizole profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROKLAR?
- What are the global sales for PROKLAR?
- What is Average Wholesale Price for PROKLAR?
Summary for PROKLAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Patent Applications: | 3,937 |
| DailyMed Link: | PROKLAR at DailyMed |
US Patents and Regulatory Information for PROKLAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forest Pharms | PROKLAR | sulfamethizole | TABLET;ORAL | 080273-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
